Cahill Represents Debt Financing Sources for Valeant Pharmaceuticals International, Inc.
Cahill represented the initial purchasers in connection with a Rule 144A/Regulation S offering of $750,000,000 aggregate principal amount of 8.500% senior notes due 2027 by Valeant Pharmaceuticals International (“VPII”), a pharmaceutical manufacturing company. Proceeds from the offering were used to refinance existing indebtedness. Cahill also represented the administrative agent and the lead arrangers in connection with a $4.565 billion term loan B facility and a $1.225 billion revolving credit facility for VPII and Valeant Pharmaceuticals International. The proceeds of the term loan facility were used to refinance existing indebtedness and the proceeds of the revolving credit facility will be used for general corporate purposes.